The Globe and Mail reports in its Wednesday, Feb. 4, edition that National Bank Financial analyst Jaeme Gloyn continues to rank Brookfield Business Partners "outperform." The Globe's David Leeder writes in the Eye On Equities column that Mr. Gloyn elevated his share target by a loonie to $44 (all figures U.S.). Analysts on average target the shares at $42.33. Mr. Gloyn says in a note: "Despite tariff risks and potential secondary impacts, we expect Brookfield's diversified portfolio of companies across sectors/geographies will continue to deliver solid results. Additionally, the proceeds from the Clarios dividend recapitalization and the secondary sale of three assets provide optionality for capital allocation and ultimately value creation as Brookfield repurchases shares and reinvests in new businesses (e.g., Chemelex, Antylia Scientific, First National, Fosber). Moreover, we continue to believe Brookfield will ultimately benefit from a more active M&A backdrop that will drive increased monetizations in the future. Lastly, we believe the conversion to a single corporate structure will improve liquidity, index inclusion and ultimately support a higher share price (expected to complete by end of Q1 2026)."